Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
Open Access
- 4 October 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 105 (10), 1542-1553
- https://doi.org/10.1038/bjc.2011.400
Abstract
Although pemetrexed, a potent thymidylate synthase (TS) inhibitor, enhances the cytoytoxic effect of platinum compounds against malignant pleural mesothelioma (MPM), novel combinations with effective targeted therapies are warranted. To this end, the current study evaluates new targeted agents and their pharmacological interaction with carboplatin–pemetrexed in human MPM cell lines. We treated H2052, H2452, H28 and MSTO-211H cells with carboplatin, pemetrexed and targeted compounds (gefitinib, erlotinib, sorafenib, vandetanib, enzastaurin and ZM447439) and evaluated the modulation of pivotal pathways in drug activity and cancer cell proliferation. Vandetanib emerged as the compound with the most potent cytotoxic activity, which interacted synergistically with carboplatin and pemetrexed. Drug combinations blocked Akt phosphorylation and increased apoptosis. Vandetanib significantly downregulated epidermal growth factor receptor (EGFR)/Erk/Akt phosphorylation as well as E2F-1 mRNA and TS mRNA/protein levels. Moreover, pemetrexed decreased Akt phosphorylation and expression of DNA repair genes. Finally, most MPM samples displayed detectable levels of EGFR and TS, the variability of which could be used for patients’ stratification in future trials with vandetanib–pemetrexed–carboplatin combination. Vandetanib markedly enhances pemetrexed–carboplatin activity against human MPM cells. Induction of apoptosis, modulation of EGFR/Akt/Erk phosphorylation and expression of key determinants for pemetrexed and carboplatin activity contribute to this synergistic interaction, and, together with the expression of these determinants in MPM samples, warrant further clinical investigation.Keywords
This publication has 55 references indexed in Scilit:
- Synergistic effect of gefitinib and rofecoxib in mesothelioma cellsMolecular Cancer, 2010
- Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- The role of folate receptor alpha (FRα) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapyBritish Journal of Cancer, 2010
- Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell linesCancer Chemotherapy and Pharmacology, 2009
- Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell linesEuropean Journal of Cancer, 2009
- Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cellsBritish Journal of Cancer, 2008
- Systemic Treatments for Mesothelioma: Standard and NovelCurrent Treatment Options in Oncology, 2008
- Epidermal Growth Factor Receptor Controls Flat Dysplastic Aberrant Crypt Foci Development and Colon Cancer Progression in the Rat Azoxymethane ModelClinical Cancer Research, 2008
- Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiationBritish Journal of Cancer, 2008
- Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol‐3 kinase pathways in non‐small cell lung cancer cellsInternational Journal of Cancer, 2005